Utah Governor Spencer Cox and BioUtah President Kelvyn Cullimore have formally recognized Co-Diagnostics, Inc. for its international expansion through the formation of CoMira Diagnostics, a joint venture in the Kingdom of Saudi Arabia. The recognition highlights Utah's emerging role as a significant player in the global life sciences industry and underscores the state's ability to produce companies that compete effectively in international markets.
Governor Cox emphasized the broader implications for Utah's economy and global standing, stating that Co-Diagnostics represents Utah-born companies competing on the world stage. Their expansion across the Middle East and North Africa reflects the strength of Utah's life sciences sector and the determination of local entrepreneurs. The governor noted pride in seeing a Utah company developing tools that help patients worldwide, indicating the venture's potential to improve healthcare accessibility in regions with growing diagnostic needs.
Kelvyn Cullimore of BioUtah, the state's life sciences trade association, confirmed Co-Diagnostics' Elite membership status within the organization and highlighted the significance of the definitive joint venture agreement signed with a company in the Kingdom of Saudi Arabia. This expansion confirms Co-Diagnostics' growing leadership and presence on the worldwide stage, representing Utah's life sciences community, which ranks among the fastest-growing in the United States.
The joint venture announcement, originally published in a November 12, 2025 press release, marks a strategic move for Co-Diagnostics as it leverages its patented molecular diagnostics platform in new international markets. The company specializes in developing advanced molecular diagnostic tests that detect and analyze nucleic acid molecules, including DNA and RNA, with applications extending to its Co-Dx PCR at-home and point-of-care platform, though this remains subject to regulatory review.
This expansion carries significant implications for global healthcare accessibility, particularly in the Middle East and North Africa regions where advanced diagnostic capabilities can address unmet medical needs. The venture represents more than corporate growth—it signals Utah's capacity to export innovative healthcare technology that can potentially transform disease detection and management worldwide. For the diagnostics industry, such international partnerships demonstrate how specialized technology platforms can bridge healthcare gaps between developed and emerging markets.
The recognition by both state government and industry leadership underscores how regional economic development initiatives can yield global health impacts. As life sciences continue to drive economic growth in Utah, successful international expansions like Co-Diagnostics' Saudi Arabian venture provide a template for other companies seeking global market penetration while addressing critical healthcare challenges through innovative diagnostic solutions.
